ArticleFrontiers in pharmacology2025
Serum amyloid A-mediated neuro-inflammation induces hippocampal neuron apoptosis and postoperative cognitive dysfunction in mice.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to explore whether serum amyloid A (SAA) triggers an inflammatory response by activating the NOD-like receptor protein 3 (NLRP3) pathway, resulting in hippocampal neuron apoptosis and cognitive impairments in mice. Methods: SAA was applied to BV-2 and HT22 cells to determine the optimal concentration and duration for stimulation. Inflammation-related and differentially expressed genes were identified through mRNA transcriptome sequencing (RNA-seq). Furthermore, apoptosis in hippocampal neurons was detected following treatment with the SAA-pretreated BV-2 cell culture medium. Furthermore, a postoperative cognitive dysfunction (POCD) mouse model was established using internal fixation of tibial fractures, followed by intraperitoneal injection of SAA and MCC950 (a selective NLRP3 inhibitor). Behavioral tests were then conducted to evaluate cognitive dysfunction in mice. Results: mRNA transcriptome sequencing revealed that SAA led to the upregulation of inflammatory factors, including interleukin-1β (IL-1β). In cultured BV-2 cells, SAA treatment activated the NLRP3 signaling pathway. Additionally, the supernatants from SAA-treated BV-2 cells significantly increased the apoptotic rate in HT22 cells and primary hippocampal neurons. Pharmacological inhibition of NLRP3 using MCC950 reduced this apoptosis. The tibial fracture intramedullary nailing technique effectively established a mouse model of POCD, with SAA administration increasing inflammatory factor levels in the hippocampus of POCD mice and impairing their cognitive abilities. However, treatment with MCC950 significantly alleviated the cognitive dysfunction induced by SAA in the POCD mice. Conclusion: SAA treatment triggers an inflammatory response through the activation of NLRP3, which subsequently causes hippocampal neuron apoptosis and impairs cognitive function in POCD mice. This dysfunction can be reversed by inhibiting NLRP3 with the administration of MCC950.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.